Head and Neck Surgery
The Clinical implications of Non-diagnostic Fine Needle Aspirates of the Thyroid Gland Robert A. Sofferman, MD (presenter); Abdel Elhosseiny; Tara Song Objective: Investigate the findings in repeat samples of patients with initial ultrasound-guided non-diagnostic fine needle aspirates (FNA) of thyroid tissue performed and interpreted over the most recent 10-year period at the University of Vermont.
Method: Retrospective review of medical records for patients with nondiagnostic thyroid FNAs. Patients were identified using a pathology laboratory information system according to specific search parameters. Patients were excluded if ultrasound guidance was not used and if documentation in the medical records was limited.
Results: A total of 239 patients met inclusion criteria. Of the 239, 145 have undergone follow-up FNA, surgical intervention, or both. There were 19 documented neoplasms after initial nondiagnostic FNA, including 2 incidental papillary microcarcinomas, 3 incidental follicular variant of papillary microcarcinomas, 1 follicular carcinoma, 7 papillary carcinomas, 2 follicular variant of papillary carcinomas, 1 non-Hodgkin DLBCL, 2 Hurthle cell neoplasms, and 1 follicular neoplasm. Excluding the 3 microcarcinomas, there were 13 significant neoplasms in the ipsilateral lobe (5%). For the 61 patients (25%) who were lost to follow-up before a definitive diagnosis was made, we cannot draw final conclusions regarding malignancy.
Conclusion:
Our study reveals significant potential for malignancy in patients with nondiagnostic FNAs. The IRB has granted permission to contact the 61 patients lost to follow-up before a definitive diagnosis was made. Delayed samples will be included as a separate analysis to profile this series of patients with nondiagnostic cytology.
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The Effect of Treating institution on Outcomes in HNCA Amy Anne D. Lassig, MD (presenter); Bruce Lindgren; Margaret Reynolds; Patricia Fernandes, DDS, MS; Samir Khariwala, MD; Bevan Yueh, MD, MPH Objective: Factors leading HNCA patients to seek radiation in a community vs academic center are incompletely described as are the effects of treating institution on outcomes. We investigated HNCA patient characteristics associated with community vs academic radiation, likelihood of successful treatment completion in both settings, and resulting survival data.
Method: A retrospective chart review was completed of all mucosal head and neck cancer patients who were treated at our institution from 2003 to 2008. Patients who received primary and adjuvant radiation were included. Numerous demographic and clinical variables were recorded, and statistical analysis was completed.
Results: A total of 386 patients were identified of which 146 patients completed treatment in the community and 213 at an academic center (27 excluded, location unknown). There was no significant difference in rate of planned treatment completion between community (94.5%) and academic centers (93.8%) (P = 1.000), or rate of treatment breaks, 23.1% and 26.9%, respectively (P = .506). The academic group, however, had more advanced disease (P = .021). The survival rate over time was statistically significant (P = .003), with academic hospitals having better survival. The 5-year survival rate for academic and community hospitals was 55.9% (95% CI = 48.1% -63.7%) and 42.9% (95% CI = 31.1% -54.6%), respectively.
Conclusion: At our institution, HNCA patients more frequently received radiation in an academic clinic. While rate of treatment completion and treatment breaks were similar between academic and community centers, academic centers treated more advanced cancer. Despite this, survival rates were better in patients treated in an academic setting.
The learning Curve in Transoral Robotic Surgery: A Multi-institutional Registry Sebastien Vergez, MD, PhD (presenter); Benjamin Lallemant; Erwann De Mones; Philippe Ceruse; Yann Mallet, MD; Karine Aubry, MD, PhD; Sylvain Morinier, MD, PhD
Objective: Assess the learning curve of transoral robotic surgery (TORS) observed in the French TORS group, gathering 7 different tertiary referral centers. The oncologic results are presented separately.
Method: A multi-institutional prospective record was done between 2008 and 2010. A total of 76 consecutive patients scheduled for a TORS have been included. The benefits observed with this technique, the operative times, conversion rate, and morbidity are described. The pitfalls encountered are detailed and responses are formulated to avoid them.
Results: Most patients had a laryngeal (supraglottic) and/or hypopharyngeal resection (65%). 30/76 patients operated by TORS would have had a transoral laser resection as alternative surgery. Tumor exposure was suboptimal in 24% of cases. Two out of 76 conversions in open-approach were necessary. In the beginning, there were 2 deaths due to complications after hemorrhage in patients with high co-morbidities. The
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median-time of set-up and procedure were respectively 60 ± 55 and 120 ± 89 minutes. The learning curve was characterized by a decrease of these durations in all the centers (P = ns), a better selection and management of patients candidates.
Conclusion: Excellent visualization and skill offered by the robotic assistance allowed transoral resection of tumors unresectable with laser surgery. Surgeons improved rapidly their exposure and resection abilities. Nevertheless, a strict selection of patients is essential. Even with a minimal invasive intent, some of them need a tracheostomy for safety reasons.
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TKi258 is Efficacious as a Multitargeted TKi in Head and Neck Squamous Cell Carcinoma Models
Larissa Sweeny, MD (presenter); Yolanda Hartman; Zhiyong Liu; Eben L. Rosenthal, MD; Joseph Knowles, MD Objective: Dovitinib (TKI28) is a multitargeted tyrosine kinase inhibitor that has not been previously investigated in the pre-clinical setting for the treatment of head and neck squamous cell carcinoma (HNSCC). Dovitinib is administered orally and targets receptors (FGFR1/2/3 and PDGF-beta) known to promote cell survival and proliferation and decrease cell apoptosis.
Method: HNSCC cell lines and human tumor samples were evaluated for FGFR1/2/3, and PDGF-beta expression levels. Cell lines (FADU, SCC1, OSC19, Cal27, SCC22A) were treated with a range of physiological concentrations of dovitinib and assessed for proliferation, cytotoxicity, and apoptosis. Mice bearing HNSCC xenografts were treated with dovitinib (20 mg/kg).
Results: Elevated expression of FGFR2, FGFR3, and PDGFbeta were indentified in HNSCC cell lines and human tumor specimens. In vitro, dovitinib reduced HNSCC cell proliferation (40-80%) and viability (40-60%). In a dose-dependent fashion, dovitinib also induced cytotoxicity and apoptosis in HNSCC cell lines. When co-cultured with fibroblasts, HNSCC cells proliferation was also decreased by dovitinib. In vivo, oral administration of dovitinib resulted in significant tumor regression and growth inhibition (67%). Disease-free survival at 75 days following completion of treatment was 33% and stable disease occurred in another 33%.
Conclusion: This is the first report to demonstrate dovitinib inhibits HNSCC cell growth in vitro and in vivo.
Head and Neck Surgery
Trends in Total laryngectomy: A Population Based Study
Patrick Tate Maddox, MD (presenter); Louise Davies, MD, MS Objective: 1) Understand time trends in total laryngectomy rates across the US, including rates of surgery, cost, length of stay, teaching status, size of hospital, and insurance payer. 2) Understand what role the paradigm shift in primary treatment of laryngeal cancer may mean for surgical outcomes, cost, and length of stay.
Method: Population-based study from 1997 to 2008 utilizing the HCUP-NIS database: a stratified sample of all US hospital discharges. The sample was all patients who had a principal procedure of ICD-9 code 30.3 or 30.4 (complete or radical laryngectomy). The unit of analysis was census area: Northeast, South, Midwest, and West.
Results: The number of laryngectomies done in the US decreased by 32% during the study period. New cases of laryngeal cancer decreased 26% during the same time. The highest rate of laryngectomy is in the South, the lowest in the Midwest and West. Mortality for the procedure is highest in the Northeast: 2.1%. Mean length of stay over the study period increased from 12.7 days to 13.9 days. Length of stay is shortest in the South. Median hospital charges rose dramatically (in 2008 dollars), from $34,934 in 1997 to $61,507 in 2008. Medicare remains the dominant insurance source.
Conclusion:
The rate of total laryngectomy has dropped more than the incidence of laryngeal cancer has dropped-suggesting that larynx preservation treatment has become dominant. Some implications of this shift are previously unexplored. As the number of procedures drops, the utility of a detailed registry to track outcomes becomes even greater.
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Ultrasound Therapy Boosts Drug Toxicity in Vitro and in Vivo Joseph Knowles, MD (presenter); Anna Sorace; C. Hope Heath, MD; Will Lancaster; Eben L. Rosenthal, MD; Kenneth Hoyt, MD Objective: Ultrasound-mediated therapy (UST) utilizes mechanical vibration of microbubble contrast agent to enhance cell permeability and anti-cancer drug delivery. Here we determine if UST can improve cisplatin or cetuximab treatment of HNSCC in vitro and in vivo.
Method: Cell permeability was assessed after UST in four HNSCC cell lines (SCC1, SCC5, Cal27, and FaDu). Combination of UST with cisplatin or cetuximab was assessed by cell survival in vitro. In vivo effects on flank tumors were measured in immune-suppressed mice.
Results: Cell permeability was 48.2 ± 4.8% greater in cells treated with UST compared to controls (P in vitro, UST alone had no effect on cell survival (P = .59), but combination treatment with cetuximab (P = .002) or cisplatin (P in vivo) (P = .81), but combination with cetuximab (P = .04) orcisplatin (P = .01) enhanced their antitumor effects. TUNEL analysis of flank tumors demonstrated increased apoptosis in UST+ cetuximab (55% vs 44%, P = .05), and UST+ cisplatin (84% vs 77%, P = .24) compared with monotherapy with either drug.
